ClinicalTrials.gg
CompletedNCT06444191Updated Jun 5, 2024

Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects

A Phase 1 interventional study of Rilzabrutinib in Healthy Volunteers, sponsored by Principia Biopharma, a Sanofi Company. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-05.

Sponsored by Principia Biopharma, a Sanofi Company (part of Sanofi) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2021, 5 years 7 months ago, and no results have been posted to the registry.
  • Registered 3 years 4 months after the study started (first participant enrolled Jan 2021, registered May 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a single-dose and multiple doses study to assess the Pharmacokinetics (PK) of rilzabrutinib as well as to evaluate the tolerability of rilzabrutinib in Japanese and Caucasian Healthy Male and Female subjects.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Principia Biopharma, a Sanofi Company is the lead sponsor of 10 studies on the registry; none are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.

First submitted after Principia Biopharma became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese subjects must have both biological parents and all four grandparents of Japanese ancestry and born in a Japanese country of origin.
  • Caucasian subjects must have four Caucasian grandparents (Hispanics of white race can be considered Caucasian).
  • Healthy adult male or non-pregnant non-lactating females, 18 to 75 years of age (inclusive) at the time of screening.
  • (BMI) ≥18 and ≤35 (kg/m2), inclusive, and a minimum body weight of 45 kg.

Additional inclusion criteria might apply.

Exclusion criteria

Exclusion Criteria:

  • Symptoms consistent with COVID-19 such as fever, cough, and shortness of breath within 14 days before Day 1.
  • Positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at screening or check-in (Day -1).
  • Known previous COVID-19 infection.
  • Use of any prescription or over-the-counter (OTC) medication, herbal products, or dietary supplements within the 7 days or 5 half-lives, whichever is longer, prior to the first study drug administration. Use of hormonal is allowed prior to and during the study.

Additional exclusion criteria might apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Cohort 1: Rilzabrutinib

    Drug: Rilzabrutinib

  • Experimental
    Cohort 2: Rilzabrutinib

    Drug: Rilzabrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum measured concentration of total rilzabrutinib in plasma (Cmax)

    Time frame: Up to 48 hours after the last rilzabrutinib dose

  2. Time from dosing to maximum measured concentration of total rilzabrutinib in plasma (tmax)

    Time frame: Up to 48 hours after the last rilzabrutinib dose

  3. Area under the concentration-time curve of total rilzabrutinib in plasma from 0 to the last measurable concentration (AUC0-last)

    Time frame: Up to 48 hours after the last rilzabrutinib dose

  4. Area under the concentration-time curve of total rilzabrutinib in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)

    Time frame: Up to 48 hours after the last rilzabrutinib dose

  5. Area under the plasma concentration-time curve of total rilzabrutinib from zero during the dosage interval (AUC0-tau)

    Time frame: Up to 48 hours after the last rilzabrutinib dose

  6. Terminal Half-Life of total rilzabrutinib in Plasma (t1/2)

    Time frame: Up to 48 hours after the last rilzabrutinib dose

  7. Apparent Total Clearance of rilzabrutinib in the plasma after oral administration (CL/F)

    Time frame: Up to 48 hours after the last rilzabrutinib dose

  8. Apparent volume of distribution after oral administration (Vd/F)

    Time frame: Up to 48 hours after the last rilzabrutinib dose

  9. Dose proportionality of rilzabrutinib

    Time frame: Up to 48 hours after the last rilzabrutinib dose

  10. Accumulation ratio (Rac)

    Time frame: Up to 48 hours after the last rilzabrutinib dose

Secondary outcomes

  1. Incidence of potentially clinically significant laboratory test, vital signs, and electrocardiogram (ECGs) abnormalities

    Time frame: Up to 14 days after rilzabrutinib dosing

  2. Number of Adverse Events (AE) / Serious Adverse Events (SAE)

    Time frame: From date of signed ICF, up to 47 days

  3. Bruton's Tyrosine Kinase (BTK) Occupancy characterization

    Time frame: Up to 48 hours after the last rilzabrutinib dose

  4. Maximum measured concentration of rilzabrutinib metabolites in plasma (Cmax)

    Time frame: Up to 48 hours after the last rilzabrutinib dose

  5. Time from dosing to maximum measured concentration of rilzabrutinib metabolites in plasma (tmax)

    Time frame: Up to 48 hours after the last rilzabrutinib dose

  6. Area under the concentration-time curve of rilzabrutinib metabolites in plasma from 0 to the last measurable concentration (AUC0-last)

    Time frame: Up to 48 hours after the last rilzabrutinib dose

  7. Area under the concentration-time curve of rilzabrutinib metabolites in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)

    Time frame: Up to 48 hours after the last rilzabrutinib dose

  8. Area under the plasma concentration-time curve of rilzabrutinib metabolites from zero during the dosage interval (AUC0-tau)

    Time frame: Up to 48 hours after the last rilzabrutinib dose

  9. Terminal Half-Life of rilzabrutinib metabolites in Plasma (t1/2)

    Time frame: Up to 48 hours after the last rilzabrutinib dose

07

Study locations

1 site
  • Investigational Site Number: 0001
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Apr 2021, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2024
First posted
Jun 5, 2024
StartActual
Jan 4, 2021
Primary completionActual
Apr 12, 2021
CompletionActual
Apr 12, 2021
Last update
Jun 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06444191
Responsible party
Sponsor
First posted
Jun 5, 2024
Start date
Jan 4, 2021
Primary completion
Apr 12, 2021
Completion
Apr 12, 2021
Last update
Jun 5, 2024

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilzabrutinib

Start the discussion